On November 12, 2025, President Donald Trump signed, legislation, H.R. 5371, extending key Medicare telehealth flexibilities on a temporary basis through January 1, 2026. Our previous client alert outlined the immediate rollback of pandemic-era telehealth rules following the government shutdown and the resulting disruption. This new legislation temporarily reverses that rollback and restores the

On May 12, 2025, President Donald Trump issued an Executive Order (EO) entitled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” with the goal of ensuring Americans pay no more for prescription drugs than other developed nations.

The EO directed the Secretary of Health and Human Services to communicate most-favored-nation (MFN) price targets to manufacturers

California has enacted two bills that will significantly impact private equity firms, management services organizations (MSOs), and physician practices operating in the state.

Assembly Bill 1415 (AB 1415) and Senate Bill 351 (SB 351) build on longstanding concerns about the corporate practice of medicine (CPOM) by expanding regulatory oversight of transactions and strengthening statutory prohibitions

In recent weeks, vaccine policy has become a flashpoint at the state level. On September 3, 2025, the governors of Oregon, California, and Washington inaugurated a West Coast Health Alliance, a regional partnership aimed at preserving scientific integrity in vaccine policy amid growing skepticism toward federal health leadership. Through this partnership, the three states

Although much of the public commentary related to the One Big Beautiful Bill Act (OBBBA) has focused on dire predictions that millions will lose coverage, healthcare leaders – including hospital system leaders, compliance teams and finance departments – should pay close attention to the regulatory details of the bill and take proactive steps now to

An article in the August 9, 2025, issue of the New England Journal of Medicine highlights the opportunity, if not the responsibility, of the bar in the private law sector to fill the gaps in healthcare access, quality, and accountability resulting from the Trump administration’s deregulation efforts regarding federal administrative agencies and legislation. Moreover, the

The U.S. Court of Appeals for the First Circuit, in United States v. Regeneron, has joined the Sixth and Eighth Circuits in adopting the “but-for” standard to find that a violation of the Anti-Kickback Statute (AKS) triggers the False Claim Act (FCA). The First, Sixth, and Eighth Circuits have adopted the burdensome “but-for” causation standard